Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches
Age-related macular degeneration (AMD) constitutes a prevalent, chronic, and progressive retinal degenerative disease of the macula that affects elderly people and cause central vision impairment. Despite therapeutic advances in the management of neovascular AMD, none of the currently used treatment...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-11-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/21/21/8242 |
| _version_ | 1797548869783912448 |
|---|---|
| author | Federico Ricci Francesco Bandello Pierluigi Navarra Giovanni Staurenghi Michael Stumpp Marco Zarbin |
| author_facet | Federico Ricci Francesco Bandello Pierluigi Navarra Giovanni Staurenghi Michael Stumpp Marco Zarbin |
| author_sort | Federico Ricci |
| collection | DOAJ |
| description | Age-related macular degeneration (AMD) constitutes a prevalent, chronic, and progressive retinal degenerative disease of the macula that affects elderly people and cause central vision impairment. Despite therapeutic advances in the management of neovascular AMD, none of the currently used treatments cures the disease or reverses its course. Medical treatment of neovascular AMD experienced a significant advance due to the introduction of vascular endothelial growth factor inhibitors (anti-VEGF), which dramatically changed the prognosis of the disease. However, although anti-VEGF therapy has become the standard treatment for neovascular AMD, many patients do not respond adequately to this therapy or experience a slow loss of efficacy of anti-VEGF agents after repeated administration. Additionally, current treatment with intravitreal anti-VEGF agents is associated with a significant treatment burden for patients, caregivers, and physicians. New approaches have been proposed for treating neovascular AMD. Among them, designed ankyrin repeat proteins (DARPins) seem to be as effective as monthly ranibizumab, but with greater durability, which may enhance patient compliance with needed injections. |
| first_indexed | 2024-03-10T15:06:54Z |
| format | Article |
| id | doaj.art-454bab878a45488dafb6df66cf057fd0 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T15:06:54Z |
| publishDate | 2020-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-454bab878a45488dafb6df66cf057fd02023-11-20T19:41:46ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-11-012121824210.3390/ijms21218242Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming ApproachesFederico Ricci0Francesco Bandello1Pierluigi Navarra2Giovanni Staurenghi3Michael Stumpp4Marco Zarbin5Department of Experimental Medicine, University Tor Vergata, Viale Oxford, 00133 Rome, ItalyScientific Institute San Raffaele, University Vita Salute, 20132 Milan, ItalyFondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, ItalyUniversity Eye Clinic Luigi Sacco Hospital, 20157 Milan, ItalyMolecular Partners AG—Wagistrasse, 14 8952 Zurich-Schlieren, SwitzerlandInstitute of Ophthalmology and Visual Science, Rutgers-New Jersey Medical School, Newark, NJ 07103, USAAge-related macular degeneration (AMD) constitutes a prevalent, chronic, and progressive retinal degenerative disease of the macula that affects elderly people and cause central vision impairment. Despite therapeutic advances in the management of neovascular AMD, none of the currently used treatments cures the disease or reverses its course. Medical treatment of neovascular AMD experienced a significant advance due to the introduction of vascular endothelial growth factor inhibitors (anti-VEGF), which dramatically changed the prognosis of the disease. However, although anti-VEGF therapy has become the standard treatment for neovascular AMD, many patients do not respond adequately to this therapy or experience a slow loss of efficacy of anti-VEGF agents after repeated administration. Additionally, current treatment with intravitreal anti-VEGF agents is associated with a significant treatment burden for patients, caregivers, and physicians. New approaches have been proposed for treating neovascular AMD. Among them, designed ankyrin repeat proteins (DARPins) seem to be as effective as monthly ranibizumab, but with greater durability, which may enhance patient compliance with needed injections.https://www.mdpi.com/1422-0067/21/21/8242age-related macular degenerationneovascular AMDneovascularizationvascular endothelial growth factoranti-VEGFAng-2 |
| spellingShingle | Federico Ricci Francesco Bandello Pierluigi Navarra Giovanni Staurenghi Michael Stumpp Marco Zarbin Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches International Journal of Molecular Sciences age-related macular degeneration neovascular AMD neovascularization vascular endothelial growth factor anti-VEGF Ang-2 |
| title | Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches |
| title_full | Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches |
| title_fullStr | Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches |
| title_full_unstemmed | Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches |
| title_short | Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches |
| title_sort | neovascular age related macular degeneration therapeutic management and new upcoming approaches |
| topic | age-related macular degeneration neovascular AMD neovascularization vascular endothelial growth factor anti-VEGF Ang-2 |
| url | https://www.mdpi.com/1422-0067/21/21/8242 |
| work_keys_str_mv | AT federicoricci neovascularagerelatedmaculardegenerationtherapeuticmanagementandnewupcomingapproaches AT francescobandello neovascularagerelatedmaculardegenerationtherapeuticmanagementandnewupcomingapproaches AT pierluiginavarra neovascularagerelatedmaculardegenerationtherapeuticmanagementandnewupcomingapproaches AT giovannistaurenghi neovascularagerelatedmaculardegenerationtherapeuticmanagementandnewupcomingapproaches AT michaelstumpp neovascularagerelatedmaculardegenerationtherapeuticmanagementandnewupcomingapproaches AT marcozarbin neovascularagerelatedmaculardegenerationtherapeuticmanagementandnewupcomingapproaches |